Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
Epistemonikos ID: 2d0fc8fa9d512aade9b9f4ddaf70a3a5b153d43c
First added on: May 07, 2024